Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple questionnaire reveal how COPD patients really feel?

NCT ID NCT01651676

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a questionnaire called VQ11 can accurately measure changes in quality of life for people with COPD who start taking a long-acting bronchodilator. Fifty-seven stable COPD patients filled out the VQ11 before and after three months of treatment. The goal was to see if a drop of 5 points on the VQ11 score reflects real improvement in daily life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
long-acting bronchodilator (beta-2 agonist or anticholinergic drug)
What this could lead to
If successful, this could show that the VQ11 questionnaire is a reliable tool for measuring quality-of-life improvements in COPD patients.
What could go wrong
This is a small, completed study focused on validating a questionnaire, not testing a new treatment. Results may not apply to all COPD patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

57 people

The number who actually took part.

Start date

Feb 2013

Finished

Dec 2015

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * COPD patient with stage II, III ou IV justifying a LABD * Patient in stable state (without exacerbation in the previous 6 weeks) * Clinical criteria: dyspnoea stage I ou more (MMRC scale) * Adult over 18 years old. * Patients naïve from LABD treatment. Exclusion Criteria: * Other associated pathology (bronchiectasia...) * Heart disorder with a prevailing role in the dyspnoea * Cardiac decompensation in the previous year * Pregnancy and lactating * Women in genital activity without efficient contraception method (IUD or estrogen-progestin pill) * Lack of social insurance * Patient non compliant to protocol, at the investigator's appreciation * Simultaneous participation to other clinical trial. * adult under judicial protection (tutor or curator).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD

Contacts and locations

Locations

  • CH Creil

    Creil, 60109, France

  • CH de DOUAI

    Douai, 59507, France

  • CHRU de Lille

    Lille, 59037, France

  • CHU Amiens Nord

    Amiens, 80054, France

  • CHU Amiens Sud

    Amiens, 80054, France

  • CHU de Rouen

    Rouen, 76000, France

  • Centre Hospitalier de Chauny

    Chauny, 02300, France

  • Centre Hospitalier de Compiègne

    Compiègne, 60200, France

  • Centre Médical

    Compiègne, 60200, France

  • Centre Médical

    Denain, 59220, France

  • Centre Médical

    Le Havre, 76600, France

  • Centre hospitalier de St Quentin

    Saint-Quentin, 02321, France

  • Clinique de l'Europe

    Amiens, 80000, France

  • Hopital Jacques MONOD

    Le Havre, 76083, France

  • Hopital Maison Blanche

    Reims, 51092, France

  • Résidence Saint Michel

    Valenciennes, 59300, France

  • Zac Gouraud

    Soissons, 02200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.